On the other hand, Song et al. [49] conducted a study in adriamycin-induced nephropathy rats and reported that MSCs can attenuate the nephropathy by diminishing oxidative stress and inhibiting the inflammation via downregulation of NFκB. These findings are consistent with our findings, which revealed a considerable increase in NFκB expression in the cisplatin group, which was reduced after treatment with ADMSCs. Here, NFKB1 is linked to kidney disorder.